Çocukluk ve ergenlik döneminde büyüme hormonu eksikliği tanı ve tedavisi uzlaşı raporu (Bölüm 2) büyüme hormonu eksikliği tedavisi

Büyüme hormonu eksikliğinde büyüme hormonu (BH) tedavisi ile nihai boyun normal sınırlar içine geldiği çeşitli çalışmalarda gösterilmiştir. Ancak, büyüme hormonu tedavisinin etkin olabilmesi için çeşitli faktörlerin (BH dozu, başlama yaşı, verilme sıklığı gibi) göz önüne alınması ve değerlendirilmesi gerekmektedir. Bu yazıda çocukluk ve adolesan döneminde büyüme hormonu eksikliğinin tedavisi ile ilgili olarak kanıtlara ve uzmanların görüşlerine dayanarak Türkiye’deki Ulusal Pediyatrik Endokrinoloji Derneği’nin önerileri sunulmuştur.

Anahtar Kelimeler:

Büyüme hormonu, Türkiye, Eksiklik hastalıkları, Ergen, Çocuk, Hormon replasman tedavisi, Görüş birliği, Örgütler

Diagnosis and treatment of growth hormone deficiency in childhood and adolescence: Consensus guidelines from the national pediatric endocrinology association in Turkey (Part 2) treatment of growth hormone deficiency

Growth hormone (GH) treatment results in normalization of final height in growth hormone deficiency of childhood. There are various aspects of growth hormone treatment that have to be taken into consideration in order to optimize final height of the children with growth hormone deficiency on GH treatment. This summary statement from the National Pediatric Endocrinology Association aims to provide guidelines for the use of GH in childhood and adolescence based on the evidence from the literature and experience of the treating physicians in Turkey.

Keywords:

Growth Hormone, Turkey, Deficiency Diseases, Adolescent, Child, Hormone Replacement Therapy, Consensus, Organizations,

___

1. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Guidelines for the use of growth hormone in children with short stature: A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. J Pediatr 1995; 127: 857-67.
2. Saggese G, Ranke MB, Saenger P, et al. Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Horm Res 1998; 50:320-40.
3. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary Statement of the GH Research Society. J Clin Endocrinol Metab 2000; 85:3990-3.
4. Consensus: Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the growth hormone research society. J Clin Endocrinol Metab 2001; 86:1868-70.
5. Tanaka T, Cohen P, Clayton PE, Laron Z, Hintz RL, Sizonenko PC. Diagnosis and management of growth hormone deficiency in childhood and adolescence -Part 2: Growth hormone treatment in growth hormone deficient children. Growth hormone & IGF Research 2002; 12:323-41.
6. Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003: 415-21.
7. Strother DR, Pollack IF, Fisher PG, et al. Tumors of the central nervous system. In: Principles and practice of pediatric oncology. Pizzo PA, Poplock DB (eds) Philadelphia: Lippincott 2002: 751-824.
8. Swerdlow AJ, Reddingius REHHA, Spoudeas HA, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000; 85:4444-9.
9. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: A report from the childhood cancer survivor study. J Clin Endocrinol Metab 2002; 87:3136-41.
10. Cohen P, Bright MG, Rogol AD, Kappelgaard AM, Rosenfeld RG. On Behalf of The American Norditropin Clinical Trials Group. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: Implications for efficacy and safety. J Clin Endocrinol Metab 2002; 87:90-8.
11. Tanaka T. Global situation of growth hormone treatment in growth hormone deficient children. Horm Res 1999; 51:75-80.
12. Blethen SL, Baptista J, Kuntze J, Foley T, La Franchi S, Johanson A. Adult height in growth hormone-deficient children treated with biosynthetic GH. The genentech growth study group. J Clin Endocrinol Metab 1997; 82:418-20.
13. Cutfield WS, Lindberg A, Chatelain P, et al. Final height following growth hormone treatment of idiopathic growth hormone deficiency in KIGS. In: Ranke MB, Wilton P (eds). Growth Hormone Therapy in KIGS-10 Years Experience. Heidelberg: Johann Ambrosius Barth Verlag 1999: 93-109.
14. Ranke MB, Lindberg A, Chatelain P, et al. On Behalf of the KIGS International Board. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab 1999; 84:1174-83.
15. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279:563-6.
16. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor -I and risk of breast cancer. Lancet 1998; 351:1393-6.
17. Lanes R, Jakubowicz S. Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children? J Pediatr 2002: 141:606-10.
18. Hibi I, Tanaka T. Final height of patients with idiopathic growth hormone deficiency after long-term growth hormone treatment. Acta Endocrinol 1989; 120:409-15.
19. Price DA, Ranke MB. Final height following growth hormone treatment. In: Ranke MB, Gunnarsson R, eds. Progress in Growth Hormone Therapy-5 years of KIGS. Mannheim: J&J Verlag 1994: 129-44.
20. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 1972; 35:665-70.
21. Martha PM, Gorman KM, Blizzard RM, Rogol AD, Veldhuis JD. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab 1992; 74:336-44.
22. Stanhope R, Uruena M, Hindmarch P, Leiper AD, Brook CGD. Management of growth hormone deficiency through puberty. Acta Paediatr Scand 1998; 372:47-52.
23. Albertsson-Wikland K, Alm F, Aronsson S, et al. Effect of growth hormone (GH) during puberty in GH- deficient children: preliminary results from an ongoing randomized tiral with different dose regimens. Acta Paediatr 1999; 428:80-4.
24. Mauras N, Attie K, Reiter E, Saenger P, Baptista J. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 2000; 85:3653-60.
25. Ranke MB, Lindberg A, Martin DD, et al. On Behalf of the Kabi International Growth Study of the Pfizer International Growth Database. The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 2003; 88:4748-53.
26. Tanaka T, Komatsu K, Takada G, Miyashita M, Ohno T. Prediction of adult height in healthy Japanese children. Acta Paediatr 1996; 417:57-60.
27. Kohn B, Julius JR, Blethen SL. Combined use of growth hormone and gonadotropin-releasing hormone analogues: The National Cooperative Growth Study Experience. Pediatrics 1999: 1014-17.
28. Reiter EO, Lindberg A, Ranke MB, et al. On Behalf of the KIGS International Board. The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency. Horm Res 2003; 60:68-73.
29. Mericq MV, Eggers M, Avila A, Cutler GB, Cassorla F. Near final height in pubertal growth hormone (GH)-deficient patients treated with luteinizing hormone- releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000; 85:569-73.
30. Mul D, Wit JM, Oostdijk W, Van den Broeck J. On Behalf of the Dutch Advisory Group on Growth Hormone. The effect of pubertal delay by GnRH agonist in GH deficient children on final height. J Clin Endocrinol Metab 2001; 80:4655-6.